Citations

Clear

4610 citation(s) found for "Lu, Brian".

Surgical Outcomes in Zenker Diverticula: A Multicenter, Prospective, Longitudinal Study
Howell, Rebecca J. , Johnson, Christopher , Allen, Jacqui , Altaye, Mekibib , Bayan, Semirra L. , Belafsky, Peter C. , Cervenka, Brian , deSilva, Brad W. , Dion, Gregory R. , Ekbom, Dale C. , Friedman, Aaron D. , Fritz, Mark A. , Kasperbauer, Jan L. , Kim, Brandon , Kuhn, Maggie A. , Madden, Lyndsay L. , Matrka, Laura , Mayerhoff, Ross , McKeon, Mallory , Piraka, Cyrus , Rosen, Clark A. , Wahab, Shaun A. , Wilson, Keith , Wright, Carter , Young, VyVy N. , Postma, Gregory N. , Collaborative, Prospective OUtcomes of Cricopharyngeal Hypertonicity (POUCH), Howell, Rebecca , Bayan, Semirra, Belafsky, Peter , deSilva, Brad , Dion, Greg , Ekbom, Dale , Friedman, Aaron D , Giliberto, John Paul , Kasperbauer, Jan , Krekeler, Brittany N , Kuhn, Maggie , Ma, Yue , Matrka, Laura , Mayerhoff, Ross , Rosen, Clark , Tabangin, Meredith , Young, Vyvy , Bayan, Semirra , Amin, Milan R , Giliberto, John Paul , Guardiani, Elizabeth , Kwak, Paul E. , Tabangin, Meredith E. , Wilson, Keith, Wright, Carter, Collaborative, Prospective OUtcomes of Cricopharyngeal Hypertonicity (POUCH)

Mayo Clinic

The Laryngoscope | May 16, 2023 | Volume: 134 | Issue: 1 | Pages: 97-102

10.1002/lary.30753 | PMID 37191092 Get It

ObjectiveTo compare improvement in patient‐reported outcomes (PROM) in persons undergoing endoscopic and open surgical management of Zenker diverticula (ZD).MethodologyProspective, multicenter cohort study of all individuals enrolled in the Prospective OUtcomes of Cricopharyngeus Hypertonicity (POUCH) Collaborative who underwent surgery for ZD. Patient survey, radiography reports, and the 10‐item Eating Assessment Tool (EAT‐10) pre‐ and post‐procedure were abstracted from a REDCap database, which summarized means, medians, percentages, and frequencies of. Outcome based on operative intervention (endoscopic vs. open) was compared using t‐test, Wilcoxon rank sum test or chi‐square test, as appropriate.ResultsOne hundred and forty‐seven persons were prospectively followed. The mean age (SD) of the cohort was 68.7 (11.0). Overall, 66% of patients reported 100% improvement in EAT‐10; 81% of patients had greater than 75% improvement; and 88% had greater than 50% improvement. Endoscopic was used for n = 109 patients, and open surgical intervention was used for n = 38. The median [interquartile range, IQR] EAT‐10 percent improvement for endoscopic treatment was 93.3% [72, 100], and open was 100% [92.3, 100] (p = 0.05). The incidence of intraoperative complications was 3.7% for endoscopic and 7.9% for open surgical management. The median [IQR] in follow‐up was 86 and 97.5 days, respectively.ConclusionBoth endoscopic and open surgical management of ZD provide significant improvement in patient‐reported outcomes. The data suggest that open diverticulectomy may provide a modest advantage in symptomatic improvement compared to endoscopic management. The data suggest that the postoperative complication rate is higher in the open surgical group.Level of Evidence3 Laryngoscope, 134:97–102, 2024
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms
Eads, Jennifer R. , Hálfdánarson, Þorvarður R. , Asmis, Tim, Belizzi, Andrew M, Bergsland, Emily K. , Dasari, Arvind , El‐Haddad, Ghassan , Mittra, Erik , Myrehaug, Sten , Nakakura, Eric K. , Raj, Nitya , Untch, Brian R. , Vijayvergia, Namrata , Chan, Jennifer A. , Myrehaug, Sten , Soares, Heloisa P , Untch, Brian , Halfdanarson, Thorvardur R , Dasari, Arvind N , Frumovitz, Michael , Meyer, Joshua E. , Soares, Heloisa P.

Mayo Clinic

Endocrine-Related Cancer | May 15, 2023 | Volume: 30 | Issue: 8 | Pages: No page available

10.1530/erc-22-0206 | PMID 37184955 Get It

High-grade neuroendocrine neoplasms are a rare disease entity and account for approximately 10% of all neuroendocrine neoplasms. Because of their rarity, there is an overall lack of prospectively collected data available to advise practitioners as to how best to manage these patients. As a result, best practices are largely based on expert opinion. Recently, a distinction was made between well-differentiated high-grade (G3) neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas, and with this, pathologic details, appropriate imaging practices and treatment have become more complex. In an effort to provide practitioners with the best guidance for the management of patients with high-grade neuroendocrine neoplasms of the gastrointestinal tract, pancreas, and gynecologic system, the North American Neuroendocrine Tumor Society convened a panel of experts to develop a set of recommendations and a treatment algorithm that may be used by practitioners for the care of these patients. Here, we provide consensus recommendations from the panel on pathology, imaging practices, management of localized disease, management of metastatic disease and surveillance and draw key distinctions as to the approach that should be utilized in patients with well-differentiated G3 neuroendocrine tumors vs poorly differentiated neuroendocrine carcinomas.
Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Wang, Qiao-Li , Ma, Chao , Yuan, Chen , Shi, Qian , Wolpin, Brian M. , Zhang, Yin , Fuchs, Charles S. , Meyer, Jeffrey , Zemla, Tyler , Cheng, En , Kumthekar, Priya , Guthrie, Katherine A. , Couture, Félix , Kuebler, Philip , Kumar, Pankaj , Tan, Benjamin , Krishnamurthi, Smitha , Goldberg, Richard M. , Blanke, Charles D. , Shields, Anthony F. , Meyerhardt, Jeffrey A. , Ng, Kimmie , Kuebler, J. Philip , Venook, Alan P , Shields, Anthony F , O'Reilly, Eileen M , Meyerhardt, Jeffrey A , Ng, Kimmie , Shi, Qian , Zemla, Tyler J , Yuan, Chen , Venook, Alan P. , O’Reilly, Eileen M. , Cheng, En

Mayo Clinic

Clinical Cancer Research | May 11, 2023 | Volume: 29 | Issue: 14 | Pages: 2621-2630

10.1158/1078-0432.ccr-23-0447 | PMID 37289007 Get It

Abstract Purpose: To assess whether higher plasma 25-hydroxyvitamin D [25(OH)D] is associated with improved outcomes in colon cancer and whether circulating inflammatory cytokines mediate such association. Experimental Design: Plasma samples were collected from 1,437 patients with stage III colon cancer enrolled in a phase III randomized clinical trial (CALGB/SWOG 80702) from 2010 to 2015, who were followed until 2020. Cox regressions were used to examine associations between plasma 25(OH)D and disease-free survival (DFS), overall survival (OS), and time to recurrence (TTR). Mediation analysis was performed for circulating inflammatory biomarkers of C-reactive protein (CRP), IL6, and soluble TNF receptor 2 (sTNF-R2). Results: Vitamin D deficiency [25(OH)D <12 ng/mL] was present in 13% of total patients at baseline and in 32% of Black patients. Compared with deficiency, nondeficient vitamin D status (≥12 ng/mL) was significantly associated with improved DFS, OS, and TTR (all Plog-rank<0.05), with multivariable-adjusted HRs of 0.68 (95% confidence interval, 0.51–0.92) for DFS, 0.57 (0.40–0.80) for OS, and 0.71 (0.52–0.98) for TTR. A U-shaped dose–response pattern was observed for DFS and OS (both Pnonlinearity<0.05). The proportion of the association with survival that was mediated by sTNF-R2 was 10.6% (Pmediation = 0.04) for DFS and 11.8% (Pmediation = 0.05) for OS, whereas CRP and IL6 were not shown to be mediators. Plasma 25(OH)D was not associated with the occurrence of ≥ grade 2 adverse events. Conclusions: Nondeficient vitamin D is associated with improved outcomes in patients with stage III colon cancer, largely independent of circulation inflammations. A randomized trial is warranted to elucidate whether adjuvant vitamin D supplementation improves patient outcomes.
Correction: Garza-Lopez et al. Protocols for Generating Surfaces and Measuring 3D Organelle Morphology Using Amira. Cells 2022, 11, 65
Vue, Zer , Katti, Prasanna , Neikirk, Kit , Biete, Michelle , Lam, Jacob , Beasley, Heather K. , Rodman, Taylor, Christensen, Trace , Salisbury, Jeffrey L., Vang, Larry , Mungai, Margaret , AshShareef, Salma, Murray, Sandra , Shao, Jianqiang, Pereira, Renata O. , Hinton, Antentor , Katti, Prasanna , Biete, Michelle , Beasley, Heather K , Murray, Sandra A , Pereira, Renata O , Hinton, Antentor , Garza-López, Edgar , Marshall, Andrea G. , Streeter, Jennifer , Glancy, Brian , Abel, E. Dale

Mayo Clinic

Cells | May 11, 2023 | Volume: 12 | Issue: 10 | Pages: 1356

10.3390/cells12101356 | PMID 37408281 Get It

In the original publication [...]
Feasibility and acceptability of remote smartphone cognitive testing in frontotemporal dementia research
Taylor, Jack C. , Heuer, Hilary W. , Clark, Annie L , Wise, Amy B. , Manoochehri, Masood , Forsberg, Leah K. , Mester, Carly , Rao, Meghana , Brushaber, Daniell, Kramer, Joel H. , Welch, Ariane E., Kornak, John , Kremers, Walter K. , Domoto‐Reilly, Kimiko , Fields, Julie A. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Hall, Matthew , Huey, Edward D. , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Pressman, Peter , Rankin, Katherine P. , Ratnasiri, Buddhika , Wong, Bonnie , Gorno‐Tempini, Maria Luisa , Rosen, Howard J. , Boxer, Adam L. , Staffaroni, Adam M. , Taylor, Jack Carson , Staffaroni, Adam M , Pascual, Belen , Kremers, Walter K , Domoto-Reilly, Kimiko , Brushaber, Danielle , Appleby, Brian S. , Dickerson, Bradford Clark , Grossman, Murray , Irwin, David J. , Lapid, Maria I. , Litvan, Irene , Masdeu, Joseph C , Nevler, Naomi , Rojas, Julio C. , Tartaglia, Maria Carmela , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | May 10, 2023 | Volume: 15 | Issue: 2 | Pages: No page available

10.1002/dad2.12423 | PMID 37180971 Get It

AbstractIntroductionRemote smartphone assessments of cognition, speech/language, and motor functioning in frontotemporal dementia (FTD) could enable decentralized clinical trials and improve access to research. We studied the feasibility and acceptability of remote smartphone data collection in FTD research using the ALLFTD Mobile App (ALLFTD‐mApp).MethodsA diagnostically mixed sample of 214 participants with FTD or from familial FTD kindreds (asymptomatic: CDR®+NACC‐FTLD = 0 [N = 101]; prodromal: 0.5 [N = 49]; symptomatic ≥1 [N = 51]; not measured [N = 13]) were asked to complete ALLFTD‐mApp tests on their smartphone three times within 12 days. They completed smartphone familiarity and participation experience surveys.ResultsIt was feasible for participants to complete the ALLFTD‐mApp on their own smartphones. Participants reported high smartphone familiarity, completed ∼ 70% of tasks, and considered the time commitment acceptable (98% of respondents). Greater disease severity was associated with poorer performance across several tests.DiscussionThese findings suggest that the ALLFTD‐mApp study protocol is feasible and acceptable for remote FTD research.HIGHLIGHTS The ALLFTD Mobile App is a smartphone‐based platform for remote, self‐administered data collection. The ALLFTD Mobile App consists of a comprehensive battery of surveys and tests of executive functioning, memory, speech and language, and motor abilities. Remote digital data collection using the ALLFTD Mobile App was feasible in a multicenter research consortium that studies FTD. Data was collected in healthy controls and participants with a range of diagnoses, particularly FTD spectrum disorders. Remote digital data collection was well accepted by participants with a variety of diagnoses.
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Altman, Jessica K. , Bixby, Dale L. , Fathi, Amir T. , Foran, James M. , Gojo, Ivana , Hall, Aric C. , Maness, Lori J., Mangan, James K. , Mannis, Gabriel N. , Marcucci, Guido , Moriarty, Kelsey , Ali, Moaath K. Mustafa , Neff, Jadee , Nejati, Reza , Olin, Rebecca L. , Percival, Mary-Elizabeth, Perl, Alexander E. , Rao, Dinesh S. , Shallis, Rory M. , Shami, Paul J. , Stein, Eytan M. , Stone, Richard M. , Sweet, Kendra , Uy, Geoffrey L. , Vachhani, Pankit , Cassara, Carly J., Freedman-Cass, Deborah A., Stehman, Katie, Uy, Geoffrey , Pollyea, Daniel Aaron , Jonas, Brian A. , Kishtagari, Ashwin , Lancet, Jeffrey E. , Mims, Alice S , Przespolewski, Amanda , Ravandi, Farhad , Thota, Swapna

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 8, 2023 | Volume: 21 | Issue: 5 | Pages: 503-513

10.6004/jnccn.2023.0025 | PMID 37156478 Get It

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States. Like AML, blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a myeloid malignancy. It is a rare malignancy characterized by the aggressive proliferation of precursors of plasmacytoid dendritic cells that frequently involves the bone marrow, skin, central nervous system, and other organs and tissues. This discussion section focuses on the diagnosis and management of BPDCN as outlined in the NCCN Guidelines for AML.
Opportunities to address gaps in early detection and improve outcomes of liver cancer
McMahon, Brian J. , Cohen, Chari , El‐Serag, Hashem B. , Ioannou, George N. , Roberts, Lewis R. , Block, Timothy M. , Roberts, Lewis R , Brown, Robert S. , Lok, Anna S. , Singal, Amit G.

Mayo Clinic

JNCI Cancer Spectrum | May 5, 2023 | Volume: 7 | Issue: 3 | Pages: No page available

10.1093/jncics/pkad034 | PMID 37144952 Get It

Abstract Death rates from primary liver cancer (hepatocellular carcinoma [HCC]) have continued to rise in the United States over the recent decades despite the availability of an increasing range of treatment modalities, including new systemic therapies. Prognosis is strongly associated with tumor stage at diagnosis; however, most cases of HCC are diagnosed beyond an early stage. This lack of early detection has contributed to low survival rates. Professional society guidelines recommend semiannual ultrasound-based HCC screening for at-risk populations, yet HCC surveillance continues to be underused in clinical practice. On April 28, 2022, the Hepatitis B Foundation convened a workshop to discuss the most pressing challenges and barriers to early HCC detection and the need to better leverage existing and emerging tools and technologies that could improve HCC screening and early detection. In this commentary, we summarize technical, patient-level, provider-level, and system-level challenges and opportunities to improve processes and outcomes across the HCC screening continuum. We highlight promising approaches to HCC risk stratification and screening, including new biomarkers, advanced imaging incorporating artificial intelligence, and algorithms for risk stratification. Workshop participants emphasized that action to improve early detection and reduce HCC mortality is urgently needed, noting concern that many of the challenges we face today are the same or similar to those faced a decade ago and that HCC mortality rates have not meaningfully improved. Increasing the uptake of HCC screening was identified as a short-term priority while developing and validating better screening tests and risk-appropriate surveillance strategies.
Evaluation of Digital Health Strategy to Support Clinician-Led Critically Ill Patient Population Management: A Randomized Crossover Study
Pinevich, Yuliya , Lipatov, Kirill , Barwise, Amelia , Pickering, Brian W. , Herasevich, Svetlana , Lindroth, Heidi L., Barwise, Amelia K , Lipatov, Kirill , Lindroth, Heidi , LeMahieu, Allison , Dong, Yue , Herasevich, Vitaly

Mayo Clinic

Critical Care Explorations | May 4, 2023 | Volume: 5 | Issue: 5 | Pages: e0909

10.1097/cce.0000000000000909 | PMID 37151891 Get It

OBJECTIVES: To investigate whether a novel acute care multipatient viewer (AMP), created with an understanding of clinician information and process requirements, could reduce time to clinical decision-making among clinicians caring for populations of acutely ill patients compared with a widely used commercial electronic medical record (EMR). DESIGN: Single center randomized crossover study. SETTING: Quaternary care academic hospital. SUBJECTS: Attending and in-training critical care physicians, and advanced practice providers. INTERVENTIONS: AMP. MEASUREMENTS AND MAIN RESULTS: We compared ICU clinician performance in structured clinical task completion using two electronic environments—the standard commercial EMR (Epic) versus the novel AMP in addition to Epic. Twenty subjects (10 pairs of clinicians) participated in the study. During the study session, each participant completed the tasks on two ICUs (7–10 beds each) and eight individual patients. The adjusted time for assessment of the entire ICU and the adjusted total time to task completion were significantly lower using AMP versus standard commercial EMR (–6.11; 95% CI, –7.91 to –4.30 min and –5.38; 95% CI, –7.56 to –3.20 min, respectively; p < 0.001). The adjusted time for assessment of individual patients was similar using both the EMR and AMP (0.73; 95% CI, –0.09 to 1.54 min; p = 0.078). AMP was associated with a significantly lower adjusted task load (National Aeronautics and Space Administration-Task Load Index) among clinicians performing the task versus the standard EMR (22.6; 95% CI, –32.7 to –12.4 points; p < 0.001). There was no statistically significant difference in adjusted total errors when comparing the two environments (0.68; 95% CI, 0.36–1.30; p = 0.078). CONCLUSIONS: When compared with the standard EMR, AMP significantly reduced time to assessment of an entire ICU, total time to clinical task completion, and clinician task load. Additional research is needed to assess the clinicians’ performance while using AMP in the live ICU setting.
Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE)
Rusthoven, Chad G. , Staley, Alyse , Yomo, Shoji , Bernhardt, Denise , Wandrey, Narine , Shafie, Rami A. El , Kraemer, Anna, Padilla, Oscar , Chiang, Veronica , Faramand, Andrew , Wegner, Rodney E. , Hattangadi‐Gluth, Jona A. , Lévy, Antonin , Bernstein, Kenneth , Mathieu, David , Cagney, Daniel , Grills, Inga S., Lee, Cheng-chia, Sheehan, Jason , Kluwe, Christien, Patel, Samir H. , Halasz, Lia M. , Andratschke, Nicolaus , Deibert, Christopher P., Cifarelli, Christopher P. , Debus, Jürgen, Aoyagi, Kyoko , Brown, Paul D. , Alami, Vida, Niranjan, Ajay , Lunsford, L. Dade , Camidge, D Ross, Kavanagh, Brian D. , Serizawa, Toru , Yamamoto, Masaaki, Bernhardt, Denise , Zacharia, Brad E , Andratschke, Nicolaus , Trifiletti, Daniel M , Mathieu, David , Robin, Tyler P. , Gao, Dexiang , Palmer, Joshua D. , Zacharia, Brad E. , Chan, Michael David , Braunstein, Steve , Verma, Vivek, Trifiletti, Daniel M. , Combs, Stephanie Elisabeth , Sato, Yasunori , Higuchi, Yoshinori , Kondziolka, Douglas

Mayo Clinic

JNCI: Journal of the National Cancer Institute | May 4, 2023 | Volume: 115 | Issue: 8 | Pages: 926-936

10.1093/jnci/djad073 | PMID 37142267 Get It

Abstract Introduction Historical reservations regarding stereotactic radiosurgery (SRS) for small-cell lung cancer (SCLC) brain metastases include concerns for short-interval and diffuse central nervous system (CNS) progression, poor prognoses, and increased neurological mortality specific to SCLC histology. We compared SRS outcomes for SCLC and non-small cell lung cancer (NSCLC) where SRS is well established. Methods Multicenter first-line SRS outcomes for SCLC and NSCLC from 2000 to 2022 were retrospectively collected (n = 892 SCLC, n = 4785 NSCLC). Data from the prospective Japanese Leksell Gamma Knife Society (JLGK0901) clinical trial of first-line SRS were analyzed as a comparison cohort (n = 98 SCLC, n = 814 NSCLC). Overall survival (OS) and CNS progression were analyzed using Cox proportional hazard and Fine-Gray models, respectively, with multivariable adjustment for cofactors including age, sex, performance status, year, extracranial disease status, and brain metastasis number and volume. Mutation-stratified analyses were performed in propensity score–matched retrospective cohorts of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) positive NSCLC, mutation-negative NSCLC, and SCLC. Results OS was superior for patients with NSCLC compared to SCLC in the retrospective dataset (median OS = 10.5 vs 8.6 months; P &lt; .001) and in the JLGK0901 dataset. Hazard estimates for first CNS progression favoring NSCLC were similar in both datasets but reached statistical significance in the retrospective dataset only (multivariable hazard ratio = 0.82, 95% confidence interval = 0.73 to 0.92, P = .001). In the propensity score–matched cohorts, there were continued OS advantages for NSCLC patients (median OS = 23.7 [EGFR and ALK positive NSCLC] vs 13.6 [mutation-negative NSCLC] vs 10.4 months [SCLC], pairwise P values &lt; 0.001), but no statistically significant differences in CNS progression were observed in the matched cohorts. Neurological mortality and number of lesions at CNS progression were similar for NSCLC and SCLC patients. Leptomeningeal progression was increased in patients with NSCLC compared to SCLC in the retrospective dataset only (multivariable hazard ratio = 1.61, 95% confidence interval = 1.14 to 2.26, P = .007). Conclusions After SRS, SCLC histology was associated with shorter OS compared to NSCLC. CNS progression occurred earlier in SCLC patients overall but was similar in patients matched on baseline factors. SCLC was not associated with increased neurological mortality, number of lesions at CNS progression, or leptomeningeal progression compared to NSCLC. These findings may better inform clinical expectations and individualized decision making regarding SRS for SCLC patients.
Hereditary gelsolin amyloidosis: a rare cause of cranial, peripheral and autonomic neuropathies linked to D187N and Y447H substitutions
Mendelson, Lisa , Sanchorawala, Vaishali , McCausland, Kristen , Spencer, Brian , Dasari, Surendra , Sanchorawala, Vaishali , Mendelson, Lisa , Prokaeva, Tatiana B. , Lau, K. H. Vincent , McPhail, Ellen Darcy , Kaku, Michelle C.

Mayo Clinic

Amyloid | May 4, 2023 | Volume: 30 | Issue: 4 | Pages: 357-363

10.1080/13506129.2023.2204999 | PMID 37140928 Get It